Viatris Inc vs Western Union Co — how do they compare? Viatris Inc trades at $17.71 (market cap $20.03B), while Western Union Co trades at $6.14 (market cap $1.97B). The key difference: Viatris Inc is far larger — about 10.2× Western Union Co's market cap, and Western Union Co pays the higher dividend (14.85%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Western Union Co for 96 Days on average.
| VTRS | WU | |
|---|---|---|
Market Cap | $20.03B | $1.97B |
Volume | 14,109,977 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $18.27 | $10.28 |
52-Week Low | $9.74 | $5.90 |
Typical Hold Time | 57 Days | 96 Days |
Enterprise Value | $32.15B | $1.88B |
Dividend Yield | 2.75% | 14.85% |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Western Union (WU) trades at $6.145, up 0.57% on the day, with a mixed technical signal leaning bearish in moving averages but bullish overall. The company shows strong profitability with a 43.97% ROE and a net income margin of 9.79%, though revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent earnings have missed expectations in Q1 and Q2 2026, while the pending Intermex acquisition and a $200M cost-cutting plan aim to bolster future performance amid competitive pressures.
The stock presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, supported by a consensus price target of $6.86 offering ~12% upside. However, risks include earnings volatility, regulatory hurdles for the Intermex deal, and declining revenue trends. Analyst sentiment is cautious with only 12% buy ratings, suggesting a hold stance may be prudent until earnings stabilize and strategic initiatives show clearer results.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →